IntegraGen nabs rights to colorectal cancer biomarker; BioMarker Strategies names new CEO;

> France's IntegraGen has picked up the exclusive licensing rights for the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be a predictor of progression-free survival in patients with metastatic colorectal cancer treated with anti-EGFR therapy. Release

> BioMarker Strategies named Jerry Parrott as president, CEO and director. More

Suggested Articles

Red blood cells
MedTech

BD, Babson pair up to bring capillary blood draw to pharmacies

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

by Conor Hale
An abstract image of data
MedTech

Sophia Genetics taps ex-Foundation Med CEO as chairman

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

by Conor Hale
green bacteria
MedTech

MIT's AI researchers find a new antibiotic in an old drug

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.

by Conor Hale